Physician profile
Isha Woofter
NPI 1679672232
$27,451.22
in general payments reported to CMS, 2019-2025
56 companies · $4,718 in 2025
The $4,718 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,340 · 2020: $3,154 · 2021: $3,785 · 2022: $4,180 · 2023: $3,868 · 2024: $4,408 · 2025: $4,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,767.06 |
| Education | $226.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,181.16 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Astrazeneca Pharmaceuticals LP | $3,537.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,203.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,825.02 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $1,752.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,520.91 | 2019-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $1,491.25 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $935.56 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Sanofi-Aventis U.S. LLC | $894.07 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $838.95 | 2019-2025 | Xarelto, Spravato |
| Pfizer INC. | $762.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $750.40 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $710.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $572.29 | 2019-2025 | |
| Allergan, INC. | $560.59 | 2019-2021 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $488.20 | 2019-2025 | Xifaxan |
| Ars Pharmaceuticals Operations, INC. | $448.69 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $408.31 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $330.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $286.72 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $256.43 | 2019-2025 | Zoryve, Livalo |
| Phathom Pharmaceuticals, INC. | $254.32 | 2023-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $254.30 | 2020-2025 | Ajovy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $225.72 | 2019-2025 | Eliquis |
| Avanir Pharmaceuticals, INC. | $172.03 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.35 | 2021-2023 | |
| Abbott Laboratories | $131.34 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $126.12 | 2021 | |
| Eisai INC. | $125.30 | 2020-2022 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Shield Therapeutics INC | $110.27 | 2023-2024 | Accrufer |
| Insulet Corporation | $100.56 | 2022-2024 | Omnipod |
| Dexcom, INC. | $80.93 | 2023-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $71.79 | 2024-2025 | Unithroid |
| Esperion Therapeutics, INC. | $70.15 | 2020-2024 | Nexletol |
| Axsome Therapeutics, INC. | $67.52 | 2023-2025 | Auvelity, Sunosi |
| Sumitomo Pharma America, INC. | $63.91 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $53.65 | 2023-2024 | Nuedexta |
| Lundbeck LLC | $53.02 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $51.22 | 2022-2023 | Linzess |
| Optinose US, INC. | $49.79 | 2021 | |
| Verona Pharma, INC. | $42.84 | 2025 | Ohtuvayre |
| Scilex Pharmaceuticals INC. | $39.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.67 | 2021-2022 | |
| Ethicon US, LLC | $31.34 | 2019 | |
| Daiichi Sankyo INC. | $30.40 | 2020-2021 | |
| Dynavax Technologies Corporation | $29.79 | 2023 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $27.02 | 2019 | |
| Seqirus USA INC | $23.12 | 2025 | Fluad, Flucelvax |
| Mylan Specialty L.P. | $22.49 | 2024 | Yupelri |
| Qol Medical, LLC | $19.63 | 2022 | |
| Organon LLC | $19.50 | 2025 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $15.93 | 2022 | |
| Impel Pharmaceuticals INC. | $15.67 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.85 | 2019 | |
| Vistapharm, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Woofter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.